Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Phase 2b, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients With Tourette Syndrome

NCT06315751 is registered in ClinicalTrials.gov with Noema Pharma AG as lead sponsor.

NCT NCT06315751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06315751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Phase 2b, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients With Tourette Syndrome
Lead sponsor
Noema Pharma AG
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2024
Completion date
June 30, 2026
Enrollment
164 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

tourette syndrome